Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Novartis Venture Fund
AddedFeb 13, 2024
UpdatedJun 28, 2026
Novartis Venture Fund

Novartis Venture Fund

Operating

Venture capital firm specializing in the development and investment of innovative therapeutics.

Location
Basel, Basel-Stadt, CH
Founded
1996
Firm
Compare
Portfolio
Employees
Website

Novartis Venture Fund is a venture capital firm specializing in the development and investment of innovative therapeutics. The firm focuses on biotechnology and biopharmaceuticals, investing in companies at all stages of growth and development. Their typical investment rounds include Series A, B, and C, with substantial investments in Series A (28 rounds) and Series B (22 rounds). They manage significant committed capital to foster innovation and drive patient benefits globally.

Notable portfolio companies include Acorda Therapeutics, Akebia Therapeutics, Bionano Genomics, and GentiBio. The fund is led by key partners with extensive experience in life sciences and venture capital. Novartis Venture Fund emphasizes unmet medical needs, proprietary science, and capital efficiency. They offer unique value-add services such as strategic guidance, industry connections, and operational support to help portfolio companies achieve clinical and commercial success.

Novartis Venture Fund - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments79
Current Portfolio Count43
Total Portfolio Exits1

Top Investment Stages

Series A28 (38.4%)
Series B22 (30.1%)
Series C13 (17.8%)
Series D7 (9.6%)
Seed3 (4.1%)

Stage Mix

Series A 38%Series B 30%Series C 18%Series D 10%Seed 4%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Hyku logo

Hyku

Fore Biotherapeutics logo

Fore Biotherapeutics

Mediar Therapeutics logo

Mediar Therapeutics

Capstan Therapeutics logo

Capstan Therapeutics

Immpact Bio logo

Immpact Bio

Exo Therapeutics logo

Exo Therapeutics

Expansion Therapeutics logo

Expansion Therapeutics

Flywheel logo

Flywheel

Immunitas Therapeutics logo

Immunitas Therapeutics

GentiBio logo

GentiBio

Ribon Therapeutics logo

Ribon Therapeutics

Soteria Biotherapeutics logo

Soteria Biotherapeutics

TScan Therapeutics logo

TScan Therapeutics

Faze Medicines logo

Faze Medicines

Escape Bio logo

Escape Bio

Cala Health logo

Cala Health

Twentyeight-Seven Therapeutics logo

Twentyeight-Seven Therapeutics

Neurovia logo

Neurovia

Rox Medical logo

Rox Medical

Bionano Genomics logo

Bionano Genomics

Realeve logo

Realeve

Spyre Therapeutics logo

Spyre Therapeutics

Merganser Biotech logo

Merganser Biotech

Quartet Medicine logo

Quartet Medicine

YourBio Health logo

YourBio Health

Novartis Venture Fund - Similar Investment Firms

dRx Capital logo

dRx Capital

drxcapital.com

Novit Ventures logo

Novit Ventures

novitventures.com

Nest.Bio Venture logo

Nest.Bio Venture

nest.bio

Versant Ventures logo

Versant Ventures

Roche Venture Fund logo

Roche Venture Fund

Novus Ventures logo

Novus Ventures

novus-ventures.com

Novell Ventures logo

Novell Ventures

novell.net.in

Novitas Capital logo

Novitas Capital

novitascapital.com

New Science Ventures logo

New Science Ventures

NeuroVentures Capital logo

NeuroVentures Capital

neuroventures.com

Visionary Venture Fund logo

Visionary Venture Fund

visionaryvc.com

North South Ventures logo

North South Ventures

northsouthvc.com

Novak Biddle Venture Partners logo

Novak Biddle Venture Partners

novakbiddle.com

Inbio Ventures logo

Inbio Ventures

Novel Bioventures logo

Novel Bioventures

Novartis Venture Fund - Classification

NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 5 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end